Document Detail

Paliperidone extended release: in adolescents with schizophrenia.
MedLine Citation:
PMID:  23050744     Owner:  NLM     Status:  In-Data-Review    
Paliperidone, the major active metabolite of risperidone, is an atypical antipsychotic agent formulated as an extended-release (ER) tablet suitable for once-daily oral administration. Paliperidone ER is approved for the treatment of adolescents aged 12-17 years with schizophrenia in the US (the focus of this review). It is also approved for the treatment of adults with schizophrenia or schizoaffective disorder. Paliperidone ER has shown efficacy in the treatment of patients aged 12-17 years with acutely symptomatic schizophrenia in a randomized, double-blind, parallel-group, placebo-controlled, multicenter, 6-week trial. The primary endpoint was the change from baseline in Positive and Negative Syndrome Scale (PANSS) total score to day 43 or the final assessment point post-baseline. Patients with a PANSS total score of 60-120 received one of three weight-based, fixed once-daily doses of paliperidone ER (patients weighing 29 kg to <51 kg: 1.5 mg [low-dose], 3 mg [medium], or 6 mg [high]; patients weighing ≥51 kg: 1.5 mg [low], 6 mg [medium], or 12 mg [high]), or placebo. Compared with placebo, significant improvements in mean PANSS total scores were reported for the medium-dose (3-6 mg) paliperidone ER treatment groups. There were no significant differences in mean PANSS total scores between the recipients of low-dose or high-dose paliperidone ER versus placebo. Mean PANSS total scores in the actual dose treatment groups (regardless of weight) decreased from baseline (i.e. improved) and were significantly lower for the 3, 6, and 12 mg groups than for the placebo group. Treatment-emergent adverse events were dose related in adolescents with schizophrenia who received weight-based fixed doses of paliperidone ER.
Caroline M Perry
Related Documents :
15857624 - Pharmacological and histological characterisation of nicotine-kindled seizures in mice.
23357844 - Pharmacokinetic and tolerability of i.m. disodium clodronate 200 mg/lidocaine 1%, given...
17636794 - Cannabinoid type 1 receptor antagonists (rimonabant) for smoking cessation.
12233984 - Contingent monetary reinforcement of smoking reductions, with and without transdermal n...
7992354 - Effects of rapamycin on renal hemodynamics, water and sodium excretion, and plasma leve...
16766274 - Effect of weight loss on qtc dispersion in obese subjects.
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Paediatric drugs     Volume:  14     ISSN:  1179-2019     ISO Abbreviation:  Paediatr Drugs     Publication Date:  2012 Dec 
Date Detail:
Created Date:  2012-10-11     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  100883685     Medline TA:  Paediatr Drugs     Country:  New Zealand    
Other Details:
Languages:  eng     Pagination:  417-27     Citation Subset:  IM    
Adis, Auckland, New Zealand.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  What is New in Rhabdomyosarcoma Management in Children?
Next Document:  Membrane-based oligonucleotide array developed from multiple markers for the detection of many Phyto...